Drug intelligence / Profile preview

erlotinib + foretinib

Development stage: Unknown
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of erlotinib (an EGFR tyrosine kinase inhibitor) and foretinib (a MET/RON/AXL/TIE-2/VEGFR kinase inhibitor). This combination was developed to potentially overcome resistance to EGFR TKIs in non-small cell lung cancer (NSCLC) by targeting multiple kinase pathways simultaneously. The combination has been studied in clinical trials for advanced pre-treated NSCLC patients.

Brand names: Tarceva
Other names: foretinib + erlotinib

Targets

AXL (AXL receptor tyrosine kinase)MST1R (Recepteur d'origine nantais)MET (Mesenchymal-epithelial transition factor receptor)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)TEK (Tie2)EGFR T790M (Epidermal growth factor receptor T790M mutant)VEGFR (VEGFR family)

Beyond the preview

Go deeper on erlotinib + foretinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erlotinib + foretinib.

Explore the full profile